Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Expansion of CD8 + T cells lacking Sema4D/CD100 during HIV-1 infection identifies a subset of T cells with decreased functional capacity

Emily M. Eriksson, Jeffrey M. Milush, Emily L. Ho, Mariana D. Batista, Sara J. Holditch, Chris E. Keh, Philip J. Norris, Sheila M. Keating, Steven G. Deeks, Peter W. Hunt, Jeffrey N. Martin, Michael G. Rosenberg, Frederick M. Hecht, Douglas F. Nixon

Blood (2012) 119 (3): 745–755.

https://doi.org/10.1182/blood-2010-12-324848

Published: 2012

Includes: Supplemental data

Journal Articles

A Phase I Study of Immune Gene Therapy for Patients with CLL Using a Membrane-Stable, Humanized CD154.

William G. Wierda, MD, PhD, J. Castro, MD, R. Aguillon, MD, A. Jalayer, RN, J. McMannis, PhD, C. Prussak, PhD, M. Keating, MB, BS, T. Kipps, MD, PhD

Blood (2007) 110 (11): 2040.

https://doi.org/10.1182/blood.V110.11.2040.2040

Published: 2007

Journal Articles

Complex Karyotypic Abnormalities Detected by Conventional Cytogenetic Analysis More Strongly Predict Survival Than FISH, ZAP70, or IgVH Mutation Status for Previously Treated Patients with CLL.

William G. Wierda, MD, PhD, S. O’Brien, MD, S. Faderl, MD, A. Ferrajoli, MD, G. Garcia-Manero, MD, J. Burger, MD, E. Schlette, MD, L. Abruzzo, MD, PhD, S. Lerner, MS, BA, M. Keating, MB, BS

Blood (2007) 110 (11): 2065.

https://doi.org/10.1182/blood.V110.11.2065.2065

Published: 2007

Journal Articles

Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Frontline Regimen for High-Risk Patients with CLL.

William G. Wierda, MD, PhD, S. O’Brien, MD, A. Ferrajoli, MD, S. Faderl, MD, C. Koller, MD, Z. Estrov, MD, G. Garcia-Manero, MD, S. Verstovsek, MD, M. Browning, BSN, ADN, S. Lerner, MS, BA, M. Keating, MB, BS

Blood (2007) 110 (11): 628.

https://doi.org/10.1182/blood.V110.11.628.628

Published: 2007

Journal Articles

Plasma RNA Is More Reliable Than Peripheral Blood Cells for Monitoring Molecular Response to Imatinib in Patients with Chronic Myeloid Leukemia.

W. Ma, R. Tseng, M. Gorre, I. Jilani, M. Keating, H. Kantarjian, J. Cortes, S. O’Brien, F. Giles, M. Albitar

Blood (2005) 106 (11): 2007.

https://doi.org/10.1182/blood.V106.11.2007.2007

Published: 2005

Journal Articles

Differences in Histone Acetylation Levels in CD34+ Cells between Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Correlation between Higher Levels of Histone 2B Acetylation and Survival in AML.

M. Gorre, I. Jilani, R. Chang, J. Bareng, H. Chan, M. Keating, H. Kantarjian, E. Estey, S. O’Brien, F. Giles, M. Albitar

Blood (2005) 106 (11): 2769.

https://doi.org/10.1182/blood.V106.11.2769.2769

Published: 2005

Journal Articles

4E-Binding Protein 1 (4E-BP1) in CD34+ Cells as Measured by Quantitative Flow Cytometry Is an Independent Prognostic Factor in Patients with Acute Myeloid Leukemia.

M. Gorre, I. Jilani, R. Chang, J. Bareng, H. Chan, M. Keating, H. Kantarjian, E. Estey, S. O’Brien, F. Giles, M. Albitar

Blood (2005) 106 (11): 2772.

https://doi.org/10.1182/blood.V106.11.2772.2772

Published: 2005

Journal Articles

Surface Antigens Identified by Antibody Microarray That Correlate with IgV H Mutational Status and ZAP70 Expression in CLL.

William G. Wierda, MD, PhD, S. Mulligan, MD, B. Shelvin, L. Belov, PhD, L. Rassenti, PhD, T. Kipps, MD, PhD, S. Lerner, MS, M. Thomas, PhD, H. Kantarjian, MD, M. Keating, MB, BS

Blood (2005) 106 (11): 2944.

https://doi.org/10.1182/blood.V106.11.2944.2944

Published: 2005

Journal Articles

Plasma Is a Reliable Source of mRNA for Testing IgVH Mutation Status in Patients with Chronic Lymphocytic Leukemia.

W. Ma, I. Jilani, M. Gorre, M. Keating, H. Chan, R. Tseng, H. Kantarjian, S. O’Brien, F. J. Giles, M. Albitar

Blood (2005) 106 (11): 2949.

https://doi.org/10.1182/blood.V106.11.2949.2949

Published: 2005

Journal Articles

Measurement of HSP90 and HSP70 in CD34-Positive Cells: Lower Levels in Myelodysplastic Syndrome Than in Acute Myeloid Leukemia and Correlation with Clinical Behavior.

M. Gorre, I. Jilani, R. Chang, H. Chan, R. Urcia, M. Keating, H. Kantarjian, E. Estey, S. O’Brien, F. Giles, M. Albitar

Blood (2005) 106 (11): 3426.

https://doi.org/10.1182/blood.V106.11.3426.3426

Published: 2005

Journal Articles

Weighted Prognostic Models for Survival in Untreated and Previously Treated Patients with CLL.

William G. Wierda, MD, PhD, S. OBrien, MD, X. Wang, MS, A. Ferrajoli, MD, S. Faderl, MD, D. Thomas, MD, F. Ravandi, MD, K. Do, PhD, H. Kantarjian, MD, S. Lerner, MS, M. Keating, MD

Blood (2005) 106 (11): 5012.

https://doi.org/10.1182/blood.V106.11.5012.5012

Published: 2005

Journal Articles

Serum Beta-2 Microglobulin: The Universal Independent Prognostic Factor for Patients with CLL.

William G. Wierda, MD, PhD, X. Wang, MS, S. OBrien, MD, S. Faderl, MD, A. Ferrajoli, MD, D. Thomas, MD, F. Ravandi, MD, J. Cortes, MD, F. Giles, MD, C. Koller, MD, H. Kantarjian, MD, S. Lerner, MS, M. Keating, MB BS

Blood (2005) 106 (11): 5018.

https://doi.org/10.1182/blood.V106.11.5018.5018

Published: 2005

Journal Articles

Coexistence of Mutated and Unmutated IgVH Forms in Patients with Chronic Lymphocytic Leukemia.

M. Sheikholeslami, W. Ma, J. Uyeji, K. Tornyos, L. Cone, S. Mamus, M. Keating, M. Albitar

Blood (2005) 106 (11): 4984.

https://doi.org/10.1182/blood.V106.11.4984.4984

Published: 2005

Journal Articles

Soluble Syndecan-1 (sCD138) Is an Independent Prognostic Factor in Patients with Chronic Lymphocytic Leukemia.

I. Jilani, M. Keating, W. William, A. Ferrajoli, H. Kantarjian, S. M. O’Brien, F. J. Giles, M. Albitar

Blood (2005) 106 (11): 713.

https://doi.org/10.1182/blood.V106.11.713.713

Published: 2005

Journal Articles

Salvage Therapy with Combined Cyclophosphamide (C), Fludarabine (F), Alemtuzumab (A), and Rituximab (R) (CFAR) for Heavily Pre-Treated Patients with CLL.

William G. Wierda, MD, PhD, S. OBrien, MD, A. Ferrajoli, MD, S. Faderl, MD, C. Koller, MD, F. Giles, MD, J. Cortes, MD, D. Thomas, MD, F. Ravandi, MD, G. Garcia-Manero, MD, M. Andreeff, MD, S. Lerner, MS, H. Kantarjian, MD, M. Keating, MD

Blood (2005) 106 (11): 719.

https://doi.org/10.1182/blood.V106.11.719.719

Published: 2005

Journal Articles

Hemizygous/Homozygous and Heterozygous JAK2 Mutation Detected in Plasma of Patients with Myeloproliferative Diseases: Correlation with Clinical Behavior.

W. Ma, H. Kantarjian, I. Jilani, M. Gorre, F. Giles, J. Cortes, S. Verstovsek, S. O’Brien, M. Keating, M. Albitar

Blood (2005) 106 (11): 2593.

https://doi.org/10.1182/blood.V106.11.2593.2593

Published: 2005

Journal Articles

Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia

M Beran, H Kantarjian, S O'Brien, C Koller, M al-Bitar, S Arbuck, S Pierce, M Moore, JL Abbruzzese, M Andreeff, M Keating, E Estey

Blood (1996) 88 (7): 2473–2479.

https://doi.org/10.1182/blood.V88.7.2473.bloodjournal8872473

Published: 1996

Journal Articles

A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia [letter]

E Estey, S Kornblau, S Pierce, H Kantarjian, M Beran, M Keating

Blood (1996) 88 (2): 756.

https://doi.org/10.1182/blood.V88.2.756.bloodjournal882756

Published: 1996

Journal Articles

Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase

S O'Brien, H Kantarjian, M Keating, M Beran, C Koller, LE Robertson, J Hester, MB Rios, M Andreeff, M Talpaz

Blood (1995) 86 (9): 3322–3326.

https://doi.org/10.1182/blood.V86.9.3322.bloodjournal8693322

Published: 1995

Journal Articles

Advances in the biology and treatment of B-cell chronic lymphocytic leukemia

S O'Brien, A del Giglio, M Keating

Blood (1995) 85 (2): 307–318.

https://doi.org/10.1182/blood.V85.2.307.307

Published: 1995

NARROW

Expansion of CD8 + T cells lacking Sema4D/CD100 during HIV-1 infection identifies a subset of T cells with decreased functional capacity

A Phase I Study of Immune Gene Therapy for Patients with CLL Using a Membrane-Stable, Humanized CD154.

Complex Karyotypic Abnormalities Detected by Conventional Cytogenetic Analysis More Strongly Predict Survival Than FISH, ZAP70, or IgVH Mutation Status for Previously Treated Patients with CLL.

Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Frontline Regimen for High-Risk Patients with CLL.

Plasma RNA Is More Reliable Than Peripheral Blood Cells for Monitoring Molecular Response to Imatinib in Patients with Chronic Myeloid Leukemia.

Differences in Histone Acetylation Levels in CD34+ Cells between Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Correlation between Higher Levels of Histone 2B Acetylation and Survival in AML.

4E-Binding Protein 1 (4E-BP1) in CD34+ Cells as Measured by Quantitative Flow Cytometry Is an Independent Prognostic Factor in Patients with Acute Myeloid Leukemia.

Surface Antigens Identified by Antibody Microarray That Correlate with IgV H Mutational Status and ZAP70 Expression in CLL.

Plasma Is a Reliable Source of mRNA for Testing IgVH Mutation Status in Patients with Chronic Lymphocytic Leukemia.

Measurement of HSP90 and HSP70 in CD34-Positive Cells: Lower Levels in Myelodysplastic Syndrome Than in Acute Myeloid Leukemia and Correlation with Clinical Behavior.

Weighted Prognostic Models for Survival in Untreated and Previously Treated Patients with CLL.

Serum Beta-2 Microglobulin: The Universal Independent Prognostic Factor for Patients with CLL.

Coexistence of Mutated and Unmutated IgVH Forms in Patients with Chronic Lymphocytic Leukemia.

Soluble Syndecan-1 (sCD138) Is an Independent Prognostic Factor in Patients with Chronic Lymphocytic Leukemia.

Salvage Therapy with Combined Cyclophosphamide (C), Fludarabine (F), Alemtuzumab (A), and Rituximab (R) (CFAR) for Heavily Pre-Treated Patients with CLL.

Hemizygous/Homozygous and Heterozygous JAK2 Mutation Detected in Plasma of Patients with Myeloproliferative Diseases: Correlation with Clinical Behavior.

Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia

A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia [letter]

Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase

Advances in the biology and treatment of B-cell chronic lymphocytic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only